Figure A: Design and subgrouping of the study cohort Figure B: Brief overview of key findings Disclosures: Simon Schophaus: Nothing to Disclose, Paul-Henry Koop: Nothing to Disclose, Jan Clusmann: Nothing to Disclose, Kai Markus Schneider: Nothing to Disclose, Carolin Victoria Schneider: Nothing to Disclose 1158 MASLD AND METALD: THE AMOUNT OF LIVER FAT AND NUMBER OF CARDIOMETABOLIC RISK FACTORS IN RELATION TO THE RISK OF TYPE 2 DIABETES AND CARDIOVASCULAR DISEASE Gabrielle Alblas 1 Jeroen van der Velde 1 Maarten Tushuizen 1 Wouter Jukema 1 Hildo Lamb 1 Frits Rosendaal 1 Bart van Hoek 1 Rene de Mutsert 1 Minneke Coenraad 1 , 1 Leiden University Medical Center Background: Metabolic dysfunction associated steatotic liver disease (MASLD) and metabolic alcohol-associated liver disease (MetALD), defined as the presence of liver fat in combination with at least one of five cardiometabolic risk factors and alcohol consumption of maximum 50 gram/day for women and 60 gram/day for men, is associated with an increased risk of type 2 diabetes and cardiovascular diseases
A TSA-compliant medical cooler lets you move through airports with confidence, no need to hunt for airport freezers, beg for ice, or stress about last-minute storage solutions
In the past year, Ive been talking to GLP-1 patients, as well as researchers and physicians, who are using or prescribing the drugs for an astounding range of diseases and conditions
Drug injury deadlines can be complicated because harm is not always discovered right away
Getting Started with GLP-1 Medications At Hormone Fitness, we offer a convenient and secure platform to access prescription GLP-1 medications
The Antidiabetic mechanisms of polyphenols related to increased glucagon-like peptide-1 (GLP1) and insulin signaling
